Excessive Daytime Sleepiness Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | NLS Pharma, XWPharma, Takeda, BenevolentAI Bio, Pfizer

Posted on
by

Excessive Daytime Sleepiness Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | NLS Pharma, XWPharma, Takeda, BenevolentAI Bio, Pfizer
Excessive Daytime Sleepiness Market

(Albany, USA) DelveInsight’s “Excessive Daytime Sleepiness Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Excessive Daytime Sleepiness, historical and forecasted epidemiology as well as the Excessive Daytime Sleepiness market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Excessive Daytime Sleepiness market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Excessive Daytime Sleepiness Market Forecast

 

Some of the key facts of the Excessive Daytime Sleepiness Market Report: 

  • The Excessive Daytime Sleepiness market size was valued approximately USD 4900 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • We have taken into account the most common causes of EDS in the epidemiology report, including Parkinson’s disease (PD), narcolepsy, idiopathic hypersomnia (IH), obstructive sleep apnea (OSA), and bipolar disorder (BD)
  • Compared to the EU-5 and Japan, the US had the most EDS diagnoses in 2021
  • In 2021, it was predicted that 6,857,997 people in the 7MM would have EDS that had been identified as widespread
  • Theranexus’s THN102, Axsome Therapeutics’ AXS12 (reboxetine), Avadel Pharmaceutical’s FT218 (a once-daily formulation of sodium oxybate), and a few more prospective medications are among the growing pipeline for EDS. The development stages of developing medications are late, intermediate, and early. Some of these developing items will presumably hit the market in the next few of years
  • Key Excessive Daytime Sleepiness Companies: Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Takeda, BenevolentAI Bio, Pfizer, Citrine Medicine Limited, Avadel, Axsome Therapeutics, Inc., Concert Pharmaceuticals, XWPharma, and others
  • Key Excessive Daytime Sleepiness Therapies: FT218, AXS-12, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, BEN-2001, PF-03654746, Pitolisant, FT218, AXS-12 (reboxetine), JZP-386, Valiloxybate, and others
  • Germany was predicted to have the greatest diagnosed prevalentpopulation of EDS (617,370 cases) among the European nations in 2021, followed by France with a predicted diagnosed prevalentpopulation of 512,453 cases
  • The Excessive Daytime Sleepiness market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Excessive Daytime Sleepiness pipeline products will significantly revolutionize the Excessive Daytime Sleepiness market dynamics.

 

Excessive Daytime Sleepiness Overview

The condition known as excessive daytime sleepiness (EDS) is characterised by difficulty remaining awake and alert during the day’s main waking periods, with sleep happening accidentally or at inopportune times. 

 

Get a Free sample for the Excessive Daytime Sleepiness Market Report: https://www.delveinsight.com/report-store/excessive-daytime-sleepiness-eds-market

 

Excessive Daytime Sleepiness Epidemiology

The Excessive Daytime Sleepiness epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Excessive Daytime Sleepiness Epidemiology Segmentation:

The Excessive Daytime Sleepiness market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Excessive Daytime Sleepiness
  • Prevalent Cases of Excessive Daytime Sleepiness by severity
  • Gender-specific Prevalence of Excessive Daytime Sleepiness
  • Diagnosed Cases of Episodic and Chronic Excessive Daytime Sleepiness

 

Download the report to understand which factors are driving Excessive Daytime Sleepiness epidemiology trends @ Excessive Daytime Sleepiness Epidemiology Forecast

 

Excessive Daytime Sleepiness Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Excessive Daytime Sleepiness market or expected to get launched during the study period. The analysis covers Excessive Daytime Sleepiness market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Excessive Daytime Sleepiness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Excessive Daytime Sleepiness Therapies and Key Companies

  • FT218: Avadel Pharmaceuticals
  • AXS-12: AxsomeTherapeutics
  • THN102: Theranexus
  • SUVN-G3031: Suven LifeSciences
  • Quilience: NLS Pharma
  • XW10172: XWPharma
  • TAK-994: Takeda

 

Discover more about therapies set to grab major Excessive Daytime Sleepiness market share @ Excessive Daytime Sleepiness Treatment Market

 

Excessive Daytime Sleepiness Market Drivers

  • Robust clinical pipeline
  • Support of the US FDA by granting designations
  • Recent launch of Xywav and Ozawade
  • Increasing prevalence dueto appearance of EDS as asymptom in various disorders

 

Excessive Daytime Sleepiness Market Barriers

  • High cost of therapies
  • Delay in diagnosis
  • A limited number of participants
  • Lack of practical measurement tools in diagnosis

 

Scope of the Excessive Daytime Sleepiness Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Excessive Daytime Sleepiness Companies: Avadel Pharmaceuticals, Axsome Therapeutics, Theranexus, Suven LifeSciences, NLS Pharma, XWPharma, Takeda, BenevolentAI Bio, Pfizer, Citrine Medicine Limited, Avadel, Axsome Therapeutics, Inc., Concert Pharmaceuticals, XWPharma, and others
  • Key Excessive Daytime Sleepiness Therapies: FT218, AXS-12, THN102, SUVN-G3031, Quilience, XW10172, TAK-994, BEN-2001, PF-03654746, Pitolisant, FT218, AXS-12 (reboxetine), JZP-386, Valiloxybate, and others
  • Excessive Daytime Sleepiness Therapeutic Assessment: Excessive Daytime Sleepiness current marketed and Excessive Daytime Sleepiness emerging therapies
  • Excessive Daytime Sleepiness Market Dynamics: Excessive Daytime Sleepiness market drivers and Excessive Daytime Sleepiness market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Excessive Daytime Sleepiness Unmet Needs, KOL’s views, Analyst’s views, Excessive Daytime Sleepiness Market Access and Reimbursement 

 

To know more about Excessive Daytime Sleepiness companies working in the treatment market, visit @ Excessive Daytime Sleepiness Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Excessive Daytime Sleepiness Market Report Introduction

2. Executive Summary for Excessive Daytime Sleepiness

3. SWOT analysis of Excessive Daytime Sleepiness

4. Excessive Daytime Sleepiness Patient Share (%) Overview at a Glance

5. Excessive Daytime Sleepiness Market Overview at a Glance

6. Excessive Daytime Sleepiness Disease Background and Overview

7. Excessive Daytime Sleepiness Epidemiology and Patient Population

8. Country-Specific Patient Population of Excessive Daytime Sleepiness 

9. Excessive Daytime Sleepiness Current Treatment and Medical Practices

10. Excessive Daytime Sleepiness Unmet Needs

11. Excessive Daytime Sleepiness Emerging Therapies

12. Excessive Daytime Sleepiness Market Outlook

13. Country-Wise Excessive Daytime Sleepiness Market Analysis (2019–2032)

14. Excessive Daytime Sleepiness Market Access and Reimbursement of Therapies

15. Excessive Daytime Sleepiness Market Drivers

16. Excessive Daytime Sleepiness Market Barriers

17.  Excessive Daytime Sleepiness Appendix

18. Excessive Daytime Sleepiness Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services